Proof of concept that melanoma nuclear count compares favourably with the benchmark histological prognostic feature, Breslow thickness

Abstract

AimsBreslow thickness (BT) is the most important histological prognostic feature for melanoma prognosis, but it only captures tumour size in one dimension. Adding a further measurement in a different axis has been shown to improve prognostic value. It seems reasonable that further prognostic value could be obtained by estimating the number of invasive melanoma cells using nuclear count. The aim of this study was to show proof of concept that nuclear count has prognostic value independent of BT.Methods and resultsMelanoma cell nuclei were labelled with SRY‐related HMG‐box 10 (SOX10) protein, the sections scanned and StarDist machine‐learning algorithm used to count nuclei in 102 cases of primary cutaneous melanoma. Prognostic value was assessed using survival analyses. Nuclear count correlated strongly with T category, BT and calculated tumour area (each P < 0.001), suggesting that it was a valid marker of melanoma burden. Nuclear count was a predictor for overall survival in univariable analysis [hazard ratio (HR) = 2.25, confidence interval (CI) = 1.66–3.06, P < 0.001] and multivariable analysis (HR = 2.60, CI = 1.59–4.24, P < 0.001). BT and ulceration were significant in univariable analyses, but not in multivariable models with nuclear count. Models containing nuclear count showed the best fit. Similar results were seen for melanoma‐specific and metastasis‐free survival. Nuclear count was able to stratify melanomas within a given T stage.ConclusionsThis study demonstrated proof of concept that counting melanoma nuclei may be an improved measure of invasive tumour burden compared to BT. Future studies will need to refine methods of nuclear detection and also to confirm its prognostic value.